PSYCHIATRIC ISSUES tied to the use of oral sildenafil (Viagra) for erectile dysfunction (ED) provoked strong interest at the annual meeting of the American Psychiatric Association (APA) in Toronto, Ontario, in June. Psychiatrists' craving for information, however, went unrequited. There were no formal presentations on ED, perhaps because Viagra had been approved for sale in the United States only in March. In the meeting's commercial exhibit area, representatives of the drug's manufacturer, Pfizer Inc, New York, NY, claimed they could not answer questions because the drug was not available in Canada.
Lamberg L. New Drug for Erectile Dysfunction Boon for Many, "Viagravation" for Some. JAMA. 1998;280(10):867-869. doi:10.1001/jama.280.10.867